T2 Biosystems, Inc.
View on Floor Plan:Exhibit Hall - 1731
About T2 Biosystems, Inc.
At T2 Biosystems, our mission is to improve patient management by empowering clinicians to get patients suspected of bloodstream infections on the right therapy faster than ever before. Our blood culture-independent tests accurately identify pathogenic organisms associated with sepsis in 3-5 hours, while blood culture-dependent tests can take 1-5 or more days. T2Candida® Panel is the first FDA-cleared test that identifies these organisms directly from a whole blood sample. The T2Bacteria® Panel is currently under review with the FDA and is CE Marked in the EU and other countries that accept the CE Mark. Both tests run on the T2Dx® Instrument and are helping get patients on the right therapy faster, improve patient outcomes, advance stewardship, and reduce the cost of patient management. We have a strong pipeline of products in development for pathogen identification, including bacterial resistance panels and swab testing for the superbug Candida auris, and a Lyme disease panel.
Product Categories (4)
- Diagnostic Equipment/Systems/Kits
- Laboratory Equipment/Supplies
- Laboratory Services/Medical Devices
- Medical Devices
Press Releases (1)
|Press Release Title||Release Date|
|T2 Biosystems Receives FDA Clearance to Market T2Bacteria Panel for Detection of Sepsis-Causing Pathogens||Tue. May 29|